Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study
Journal of Digestive Diseases · 2024
DOI: 10.1111/1751-2980.13270 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Rui Ping Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Infliximab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Xia XIE, Cheng LIU.
Abstract (Originalsprache)
Objectives
We conducted this multicenter, retrospective cohort study aiming to evaluate the effectiveness and safety of vedolizumab (VDZ) and infliximab (IFX) in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis (UC).
Methods
Biologic‐naïve patients with moderate‐to‐severe UC who were treated with IFX or VDZ for at least 14 weeks at three tertiary hospitals in southwest China between January 2021 and January 2023 were retrospectively included. Efficacy of the biologics was evaluated based on the steroid‐free clinical remission rate, clinical remission rate, and mucosal healing rate at Weeks 14 and 52. Adverse events related to biologic use were recorded.
Results
Altogether 122 biologic‐naïve patients with moderate‐to‐severe UC were included. No marked differences in the steroid‐free clinical remission rate and clinical remission rate were observed between the two groups at Week 14 or Week 52 ( P > 0.05). The VDZ group exhibited a higher mucosal healing rate at Week 14 compared to the IFX group (33.3% vs 16.9%, P = 0.036), while that at Week 52 did not differ between the two groups (65.6% vs 47.1%, P = 0.098). There was no statistically significant difference in the rate of adverse events between the two groups ( P = 0.071).
Conclusion
VDZ and IFX showed comparable clinical efficacy and safety profiles and can be used as viable first‐line therapeutic options for biologic‐naïve patients with moderate‐to‐severe UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
- Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Xia Xie
Förderung
- Xia XIE
- Cheng LIU
Zitieren
APA
Meng, R. P., Huang, B. B., Wei, Y. L., Lyu, L., Yang, H., Liu, C., Zhou, H. L., Liao, X. P., Zhou, J. Y., & Xie, X. (2024). Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13270
Vancouver
Meng RP, Huang BB, Wei YL, Lyu L, Yang H, Liu C, et al. Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13270
BibTeX
@article{Meng2024,
author = {Meng, Rui Ping and Huang, Bao Bao and Wei, Yan Ling and Lyu, Lin and Yang, Huan and Liu, Cheng and Zhou, Hong Li and Liao, Xi Ping and Zhou, Jian Yun and Xie, Xia},
title = {Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study},
journal = {Journal of Digestive Diseases},
year = {2024},
doi = {10.1111/1751-2980.13270}
}
EUVIMED